Trump’s healthcare picks will look to rein in GLP-1 spending: His selections to run the FDA and HHS aren’t big proponents of widespread GLP-1 use for weight loss. We explore what it could mean for the obesity drug market amid a new administration.
Most US patients want their PCP to ask about mental health: Yet fewer report that this happens. Lack o With a lack of affordable access to mental health treatment in the US, primary care providers could play a key role in identifying behavioral issues earlier.
Headspace transitions therapist network to contract and part-time roles: Telemental health companies are placing less of an emphasis on therapists and more on AI.
CMS must recalculate UnitedHealthcare’s Medicare Advantage star ratings: The ruling could be a good omen for Medicare Advantage insurers whose ratings were downgraded.
CMS must recalculate UnitedHealthcare’s Medicare Advantage star ratings: The ruling could be a good omen for Medicare Advantage insurers whose ratings were downgraded.
Consumers are willing to try at-home blood tests: We explore why companies in this market may still struggle to reel in customers despite their desire for convenience.
Pharmacy closures, medication shortages threaten access to meds: We examine some digital tools that drugmakers and pharmacies should endorse to ensure patients stay on their prescriptions.
Big 3 pharmacy benefit managers countersue FTC: They allege the FTC's case against them over insulin prices is unconstitutional. While it might be a savvy legal tactic, it shouldn’t divert attention from PBMs’ role in rising prescription drug costs.
Consumers are submitting medical scans to Elon Musk’s genAI chatbot, Grok: But Grok isn’t trained well enough on medical data, which could create a host of problems for patients.
Nearly one-quarter of working-age US adults are underinsured: More consumers are being pushed onto less generous health plans, which will inevitably result in sicker patients with higher amounts of medical debt.
Trump taps Dr. Oz to helm the CMS: We detail what the celebrity doctor’s appointment would mean for the future of Medicare, Medicaid, the Affordable Care Act, and consumers enrolled in these plans.
Docs struggle to use ChatGPT for diagnosing illnesses: Chatbots have greater diagnostic accuracy by themselves than physicians using AI. We examine how doctors can get more comfortable using AI for medical diagnostics.
Dexcom, Oura partner to integrate glucose and biometric data: The tie-up should be a symbiotic one that draws customers to each company’s devices as consumers look to uncover more information about their health.
Women drive 80% of healthcare decisions, but aren’t a marketing priority: Healthcare and pharma marketers that don’t prioritize accurate portrayals of women in their ads are leaving a massive amount of money on the table.
Pharmacy benefit managers confuse consumers and employers alike: Employers must gain a better understanding of their PBM contracts so they can steer their workers toward lower-cost drugs.
FDA says Merz Pharma’s Instagram ad is misleading: The regulator could be ramping up its oversight of drug ads on social media that involve influencers.
Trump taps RFK Jr. to lead Health and Human Services: If confirmed, the vaccine skeptic’s appointment would hold serious implications for Big Pharma.
Tech-focused primary care startup Forward shuts down: It invested too much in tech and not enough in patient care. We explore how primary care subscriptions can strike the right balance.
Pfizer explores a sale of its hospital drugs unit: The move was spurred by activist investor Starboard Value, which has put pressure on Pfizer to reduce its debts after taking a $1B stake in the company.
Amazon’s telehealth service offers upfront pricing for Prime members: This puts it in direct competition with companies like Hims & Hers and Ro. Here’s why they should be worried.